ADC Therapeutics SA filings document the regulatory record of a Swiss commercial-stage biotechnology company with common shares listed on the New York Stock Exchange. Its Form 8-K reports cover operating results, preliminary financial information, Regulation FD presentations, clinical data updates for ZYNLONTA studies, and material agreements including amendments to royalty financing arrangements.
Proxy materials describe annual general meeting matters under Swiss law, including approval of annual and consolidated financial statements, compensation report votes, discharge of directors and executive committee members, board and compensation committee elections, auditor matters and share capital governance. The filings also identify the company’s registered common shares, par value and exchange listing.
ADC Therapeutics SA announced that updated ZYNLONTA data will be presented in five oral sessions at the December 12 through December 15, 2026 ASH meeting. In LOTIS-7, 97 efficacy-evaluable patients had an 88.7% overall response rate and a 75.3% complete response rate. A Phase 2 marginal zone lymphoma study reported a 93% overall response rate and a 74.4% complete response rate among 43 efficacy-evaluable patients.
In Phase 3 LOTIS-5, ZYNLONTA plus rituximab met the primary progression-free survival endpoint versus R-GemOx (hazard ratio 0.73; two-sided p-value 0.0084), while grade 5 treatment-emergent adverse events were 13.2% versus 4.6%. ADC Therapeutics said the FDA cited concerns about benefit-risk or verification of clinical benefit for the combination. Preliminary net product revenue was estimated at $21 million for Q3 and $60 million for the first nine months of 2026, versus $16 million and $51 million in the same 2025 periods.
Cash and cash equivalents were preliminarily estimated at $189.2 million as of September 30, 2026; estimated pro forma cash was $196 million, and the company expects cash runway into 2029. ADC Therapeutics reported an $86.6 million private placement and a refinancing that reduced senior secured loan principal to $50 million, with a bullet payment in August 2029. The company said actual results had not been finalized and preliminary figures could differ materially.
ADC Therapeutics SA (ADCT) is asking shareholders to approve a move of its incorporation from Switzerland to Delaware. If completed, it would continue as ADC Therapeutics, Inc. without liquidation, dissolution or creation of a new entity. Each issued CHF 0.08-par common share would convert into one $0.10-par common share, preserving each holder’s share count. The company expects the stock to remain listed on the NYSE under ADCT; it says its business and consolidated capitalization, assets, liabilities and financial statements would be substantially the same.
Completion depends on shareholder approval and other conditions. The Redomiciliation and Constitutive Documents proposals are conditioned on each other, and the Discharge Proposal depends on both; if Delaware incorporation has not occurred by June 30, 2027, approvals of the first two lapse. Shareholder rights would differ under Delaware law and the proposed certificate and bylaws. The company says it does not expect Swiss withholding tax to be payable because its current market capitalization is substantially below the relevant amount; a 35% rate could in principle apply to the excess of equity fair market value over nominal share capital plus confirmed capital-contribution reserves. It intends to seek Swiss tax rulings.
ADC Therapeutics SA shares: Bain Capital Life Sciences Opportunities IV, L.P. reports that it may be deemed to beneficially own 14,825,625 common shares, or 9.99%, as of October 22, 2026. Its reported holdings include 7,000,000 common shares and pre-funded warrants to purchase up to 22,703,927 common shares; the beneficial-ownership figure includes 7,825,625 shares issuable upon partial warrant exercise.
The warrants cannot be exercised if doing so would cause Bain Capital to beneficially own more than 9.99% of the common shares issued and outstanding immediately after exercise. The reporting person has shared voting and dispositive power over 14,825,625 shares and no sole voting or dispositive power.
ADC Therapeutics SA (ADCT) agreed to a $86.6 million private placement, assuming cash exercise of pre-funded warrants: 12,911,347 common shares at $1.4200 each and warrants for 48,088,653 shares at $1.32400 each. Closing is expected October 22, 2026, subject to customary conditions. The company anticipates approximately $76.3 million in net proceeds and intends to use them for ZYNLONTA pipeline studies, working capital and general corporate purposes.
The loan amendment, conditioned on the placement, provides for a $70.0 million principal prepayment plus interest, fees and premiums, leaving $50.0 million of term loans. It eliminates subsequent scheduled amortization and the minimum liquidity covenant and sets a $65.0 million minimum trailing four-quarter U.S. ZYNLONTA sales covenant from the quarter ending December 31, 2026. The HCR amendment removes a $150 million change-of-control payment and reduces permitted third-party debt to $50.0 million, subject to its conditions. Preliminary, unaudited third-quarter ZYNLONTA revenue was approximately $21.0 million and cash was $189.2 million as of September 30, 2026; pro forma cash after the placement and loan payment was estimated at approximately $196 million.
ADC Therapeutics SA is reported to have a significant shareholder group led by Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack. As of June 30, 2026, they may be deemed to beneficially own 12,326,184 common shares of ADC Therapeutics, representing 9.69% of the outstanding common shares.
All reported holdings are held through funds and separately managed accounts controlled by Nantahala. The Reporting Persons have no sole voting or dispositive power over the shares; instead, they report shared voting and shared dispositive power over the full 12,326,184 shares.
ADC Therapeutics reported second-quarter 2026 net revenue of $19.2 million, up slightly from 2025, driven by higher U.S. ZYNLONTA pricing, while six‑month revenue was $40.1 million, modestly below the prior year due to lower license and milestone income. The company narrowed its net loss to $16.6 million for the quarter and $49.5 million for the first half, helped by sharply lower R&D spending after its 2025 restructuring and a non‑cash gain from revaluing HCR warrants.
Cash and cash equivalents were $219.1 million at June 30, 2026, with six‑month operating cash outflow of $41.5 million. The balance sheet shows negative shareholders’ equity of $228.2 million, reflecting an accumulated deficit of $1.69 billion, a $320.6 million deferred royalty obligation, and $116.6 million of senior secured term loans.
Clinically, ZYNLONTA plus rituximab met the primary endpoint of progression‑free survival in the Phase 3 LOTIS‑5 trial (HR 0.73; p=0.008), but the FDA expressed substantial concerns about benefit‑risk in light of higher Grade 5 events and a marginal efficacy benefit. ADC is reassessing its regulatory strategy while continuing monotherapy commercialization under accelerated approval. The LOTIS‑7 Phase 1b glofitamab combination completed enrollment with previously reported high response rates, and the company plans a Breakthrough Therapy designation request. A new 2026 restructuring will reduce the remaining global workforce by about 17% to focus resources on ZYNLONTA.
ADC Therapeutics reported second-quarter 2026 net product revenue of $18.6 million, roughly flat year over year, and total revenue of $19.2 million. Aggressive cost control cut total operating expenses to $44.7 million, down 29% from 2025, reducing the quarterly net loss to $16.6 million from $56.6 million. Adjusted operating expenses fell 22% to $37.2 million, and adjusted net loss narrowed to $16.3 million.
Cash and cash equivalents were $219.1 million at June 30, 2026, with the company stating an expected cash runway at least into 2028. A June 2026 reorganization, including a 17% workforce reduction, is expected to generate about $10 million in annualized savings.
On the clinical side, the Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab met its primary PFS endpoint, but the FDA expressed substantial concerns about benefit–risk given an imbalance in Grade 5 events and marginal treatment benefit, leaving the full-approval path under evaluation. The LOTIS-7 Phase 1b trial of ZYNLONTA plus glofitamab completed enrollment and shows high complete response rates in relapsed/refractory DLBCL, with plans to seek Breakthrough Therapy designation and explore a Phase 3 program. Investigator-initiated trials in marginal zone and follicular lymphomas report high complete response rates and durable disease control, supporting potential compendia and regulatory strategies from 2027 onward.
BlackRock, Inc. reports a significant ownership position in ADC Therapeutics SA common stock. BlackRock and certain of its business units beneficially own 6,857,815 shares of ADC Therapeutics, representing 5.4% of the outstanding common stock.
BlackRock has sole voting power over 6,765,332 shares and sole dispositive power over all 6,857,815 shares, with no shared voting or dispositive power reported. Various underlying clients and investors have the right to receive dividends and sale proceeds from these shares, but no single such person holds more than five percent of ADC Therapeutics’ total outstanding common shares. The filing is signed by Managing Director Spencer Fleming on behalf of BlackRock.
Zaki Mohamed reported acquisition or exercise transactions in this Form 4 filing.
ADC Therapeutics SA Chief Medical Officer Zaki Mohamed received an equity award in the form of restricted stock units. On June 30, 2026 he was granted 213,900 RSUs, each representing the right to receive one common share at no purchase price.
The RSUs will vest on the earlier of June 30, 2027 or a qualifying termination without cause or for good reason, provided he remains employed through the vesting date. Following this grant, Mohamed holds 896,317 common shares directly, highlighting that this is a compensation-related award rather than an open-market share purchase or sale.
GRAHAM PETER J reported acquisition or exercise transactions in this Form 4 filing.
ADC Therapeutics disclosed that Chief Legal Officer Peter J. Graham received an award of 221,100 restricted stock units (RSUs) of common shares on June 30, 2026 under an incentive award letter agreement. The RSUs vest on the earlier of June 30, 2027 or certain termination events, subject to continued employment. Each RSU represents a right to receive one common share, bringing his direct holdings to 841,640 common shares after the award.